Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS

Supplements and Featured Publications, IRAK4 Inhibition Makes a Splash in B-Cell Malignancies , Volume 1, Issue 1

In Partnership With:

Partner | Cancer Centers | <b>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James)</b>

Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.

Welcome to OncLive On Air®! I’m your host today, Ryan Scott.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Curis, we had the pleasure of speaking with Alice Mims, MD, on the utility of the IRAK4 and FLT3 inhibitor emavusertib (previously CA-4948) in heavily pretreated patients with FLT3-mutated relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. Emavusertib is under evaluation in these patient populations in the phase 1/2a TakeAim Leukemia trial (NCT04278768).

Dr Mims is a medical oncologist and an associate professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center—James in Columbus.

In our exclusive interview, Dr Mims discussed the rationale for launching the phase 1/2a investigation, noting the potential implications of these findings thus far.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Curis. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. 

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.